

**Minutes kept at extraordinary general meeting
of Probi AB (publ), Reg. No 556417-7540, held
on 29 June 2016 in Lund**

§ 1

The meeting was declared opened by Madeleine Rydberger on behalf of the board of directors.

§ 2

Madeleine Rydberger was appointed chairman of the meeting.

It was informed that the minutes were kept by Jakob Wijkander.

The meeting also resolved that other people than shareholders, proxies and advisors for shareholders were allowed to participate at the meeting.

§ 3

A list of participating shareholders and proxies and advisors for shareholders was established, see Appendix 1. The list was approved as the voting list for the meeting.

§ 4

The proposed agenda in the notice of the meeting was approved as the agenda for the meeting.

§ 5

Arne Lööv and Anders Persson were appointed to approve and sign the minutes of the meeting along with the chairman.

§ 6

The chairman described how the meeting had been summoned, and it was established that the meeting had been duly convened.

§ 7

The Chairman presented the proposal by the board of directors' on authorisation of the board to resolve on a new issue of shares, in accordance with Appendix 2.

CEO Peter Nählstedt briefly presented the acquisition of Nutraceutix. Provided an opportunity to ask questions.

It was noted that the proposal had been held available for the shareholders at the company and on its website since 8 June 2016 and that it had been sent to the shareholders that requested so. It was therefore noted that the proposal was duly presented at the meeting.

The meeting unanimously resolved in accordance with the proposal by the board of directors.

§ 8

The meeting was declared closed by the chairman.

Minutes kept by

Jakob Wijkander

Approved

Madeleine Rydberger

Approved

Arne Lööv

Anders Persson

Proposal by the Board of Directors on authorisation of the Board to resolve on a new issue of shares

The Board of Directors proposes the EGM to authorise the Board to resolve on the issue of new shares with preferential right for the company's shareholders during the period up to the company's annual general meeting 2017. The total number of shares that may be issued by virtue of the authorisation shall amount to the number of shares corresponding to issue proceeds of approximately SEK 600,000,000, and shall be within the limits of the share capital. The purpose of the authorisation is to enable financing of the company's acquisition of U.S probiotic company Nutraceutix's operations. Other terms and conditions for the new share issue shall be determined by the Board.

Lund in June 2016

Probi AB (publ)
The Board of Directors